March 25, 2020 / 8:05 PM / 15 days ago

BRIEF-Xencor And Vir Biotechnology Enter License Agreement For Use Of Xtend™ Xmab® Antibody Technology

March 25 (Reuters) - Vir Biotechnology Inc:

* XENCOR AND VIR BIOTECHNOLOGY ENTER LICENSE AGREEMENT FOR USE OF XTEND™ XMAB® ANTIBODY TECHNOLOGY IN INVESTIGATIONAL ANTIBODIES TO TREAT COVID-19

* XENCOR INC - VIR WILL HAVE NON-EXCLUSIVE ACCESS TO XENCOR’S XTEND FC TECHNOLOGY

* XENCOR INC - VIR WILL HAVE NON-EXCLUSIVE ACCESS TO XENCOR’S XTEND FC TECHNOLOGY TO EXTEND HALF-LIFE OF NOVEL ANTIBODIES

* XENCOR INC - VIR WILL BE SOLELY RESPONSIBLE FOR ACTIVITIES AND COSTS RELATED TO RESEARCH

* XENCOR INC - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED

* XENCOR INC - CONTINUES TO EVALUATE POTENTIAL IMPACT OF COVID-19 PANDEMIC ON ONGOING AND PLANNED CLINICAL STUDIES

* XENCOR INC - CURRENTLY MAINTAINING PREESTABLISHED GUIDANCE ON 2020 CORPORATE MILESTONES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below